BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.40M | -9.22M | -19.92M | -30.12M | -49.15M |
| Total Depreciation and Amortization | 3.26M | 3.99M | 2.86M | 2.24M | 1.96M |
| Total Amortization of Deferred Charges | 1.44M | 742.00K | 59.00K | 59.00K | 59.00K |
| Total Other Non-Cash Items | -22.10M | -17.57M | -6.57M | -429.00K | 14.27M |
| Change in Net Operating Assets | -11.56M | -21.82M | -6.70M | -2.10M | 4.16M |
| Cash from Operations | -32.36M | -43.87M | -30.27M | -30.35M | -28.70M |
| Capital Expenditure | -21.00K | -53.00K | -75.00K | -76.00K | -116.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.53M | 29.43M | -2.10M | -8.18M | 11.61M |
| Cash from Investing | 4.51M | 29.37M | -2.18M | -8.26M | 11.49M |
| Total Debt Issued | 19.22M | 19.22M | 19.22M | 19.22M | -- |
| Total Debt Repaid | -15.30M | -14.94M | -3.70M | -3.61M | -2.83M |
| Issuance of Common Stock | 27.26M | 16.56M | 18.17M | 22.61M | 17.04M |
| Repurchase of Common Stock | -180.00K | -180.00K | -180.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 31.00M | 20.66M | 33.51M | 38.22M | 14.21M |
| Foreign Exchange rate Adjustments | -111.00K | 22.00K | 52.00K | -101.00K | -75.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.05M | 6.18M | 1.11M | -481.00K | -3.08M |